Cours Regenicin, Inc. Other OTC
Actions
RGIN
US75887Q1022
Recherche biotechnologique et médicale
CA 2021 | - | CA 2022 | - | Capitalisation | 491 k 447 k |
---|---|---|---|---|---|
Résultat net 2021 | - 0 | Résultat net 2022 | - 0 | VE / CA 2021 | - |
Dette nette 2021 | 598 k 544 k | Dette nette 2022 | 627 k 570 k | VE / CA 2022 | - |
PER 2021 |
-2
x | PER 2022 |
-0,71
x | Employés | - |
Rendement 2021 * |
-
| Rendement 2022 |
-
| Flottant | 79,1% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/07/10 |
John Weber
DFI | Director of Finance/CFO | 74 | 13/09/10 |
J. Nelson
CTO | Chief Tech/Sci/R&D Officer | 75 | 15/07/10 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
John Weber
DFI | Director of Finance/CFO | 74 | 13/09/10 |
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/07/10 |
Varia. 1 janv. | Capi. | |
---|---|---|
+9,65% | 115 Md | |
+11,91% | 106 Md | |
-2,59% | 21,96 Md | |
-13,89% | 21,87 Md | |
-5,29% | 19,21 Md | |
-3,42% | 18,08 Md | |
-38,57% | 17,71 Md | |
+6,21% | 14,32 Md | |
+33,74% | 12,42 Md |